POLISCOPE
Back to feed
NewsSan Diego Business JournalAugust 12, 2026San Diego

Gossamer Bio prepares to submit first New Drug Application to the FDA

San Diego-based biopharmaceutical company Gossamer Bio is nearing the submission of a New Drug Application to the U.S. Food and Drug Administration. This milestone follows a decade of development, multiple leadership changes, and the previous failure of a lead drug candidate.

biotechnologypharmaceuticalsFDA approvalbusiness
Read the full story at San Diego Business Journal

Why It Matters

The submission of a New Drug Application is a critical regulatory step that determines whether the company's first drug will be authorized for public sale and medical use.

Key Facts

  • Gossamer Bio is preparing to submit a New Drug Application (NDA) to the FDA.
  • This represents the company's first potential drug approval after a decade of development.
  • The company has previously experienced the failure of a lead drug candidate.
  • The company has undergone multiple changes in CEO leadership during its development history.
  • Gossamer Bio is a publicly traded company listed on the Nasdaq under the ticker GOSS.

Who's Mentioned

organizationGossamer Bio“Biopharmaceutical company based in San Diego”otherGOSS“Nasdaq stock ticker for Gossamer Bio”organizationU.S. Food and Drug Administration“Regulatory body responsible for drug approval”locationSan Diego“Headquarters location of Gossamer Bio”